Global Endocrine Peptide Test Market To Grow At A CAGR of 8% During The Forecast Period

The global endocrine peptide test market was worth around $7.04 billion in 2021 and is predicted to grow to around $11 billion by 2028 at a CAGR rate of 8% over the forecast period.

Endocrine peptide test is performed to measure the amount of C-peptide levels in the blood serum. The peptide is a similar component to insulin and they both are proportionally equal in a body. Insulin is a content responsible for the level of glucose present in your bloodstream.

C-peptide is actually the amount of insulin present in the pancreas. The sugar level in the body is calculated via these tests. Although C-peptide has no direct bearing on the number of sugar levels, it will still reveal whether someone is diabetic or not. C-peptide also regulates the quantity of glucose in the blood.

It comprises short 31-amino acid particles. If someone has to be tested for initiation of diabetes, then they would take this test for confirmation. It also shows what type of diabetic a patient is.

The proinsulin molecule chain, peptide actually connects the A-chain to B-Chain. The glucose enters the body through the channels of peptides. Both insulin and C-peptide are deposited in equal amounts in the pancreas. Not just for diabetes, this test can also be leveraged for other clinically similar diseases. Sometimes a tumor in the pancreas or any non-cancerous growth can also be identified with the tests.

The exponential increase in the number of infected patients during the pandemic triggered a huge demand for specialist treatment methods and tests. The healthcare infrastructure that is currently available was not capable enough to treat millions of people who fell ill during the pandemic times. Any chance to improve diagnosis methods and treatments was implemented and supported by the governments to satisfy the massive demand. Hence the global endocrine peptide test market grew at a considerable rate with so many diabetic and immuno-compromised people waiting to get tested when the pandemic was in a rage. Although people suffered to commute to reach clinics and hospitals due to severe lockdowns and curfews, the demand for such testing routines increased rapidly.

The other major growth drivers of the endocrine peptides test market are the prevalence of diseases like diabetes, thyroid disorders, infertility, tumors, etc. The immunity level of the people and the obesity rates have increased massively leading to the spike in the demand for endocrine tests. The geriatric population across the world has seen a rise above normalcy and the imminent risk of chronic diseases in the older population amplify the market rate considerably.

Moreover, healthcare facilities across the world have improved and these tests are leveraged more due to such advancements in infrastructures in healthcare services. The precision rate is also increased considerably which induces more demand from the people, thereby propelling the market growth.

Mass spectrometry in these tests has improved the accuracy of results. This factor seems to have improved the consumption of the tests to a large extent. Operating home diagnostic kits for endocrine tests makes them more accessible and affordable to the people thereby improving the market rate.

The high cost that is incurred due to the consumption of these tests restrains the market growth. There is also a considerable ignorance and lack of awareness that prevails in the developing countries about the significance of these tests. This also comes off as the restraining factor for market expansion.

The global endocrine peptide test market is fragmented into its test type, end-user industry, and region. On the basis of the test type, the global market is segregated into dehydroepiandrosterone sulfate, progesterone, luteinizing hormone, thyroid prolactin, oestradiol, human chorionic gonadotropin, thyroid-stimulating hormone, and others. On the basis of the end-user industry, the market is categorized into clinics, health care centers, hospitals, and commercial laboratories

North America tops the global endocrine peptide test market rate owing to the excessive emergence of endocrine disorders in that region. Obesity rates and immuno-compromised people are also high in numbers which spikes up the demand for these tests. The increase in the geriatric population across North America is also a major contributing factor to the rise in the market rate. Western Europe stands next to North America as the second-largest contributor to the global market. Healthcare infrastructures and focus on the improvement or accessibility of healthcare services induce market growth considerably.

The key global endocrine peptide test market players are Agilent Technologies, Abbott Laboratories, Biomedical Diagnostics, Bio-Rad Laboratories, Hoffman- La Roche Ltd, ImmunoDX, Laboratory Corporation, Nano Entek, Siemens AG, Thermo Fischer Scientific Inc., and BioMerieux.

Recent Developments:

• In June 2022, at ENDO 2022, the Endocrine Society presented a clinical study about the development of PEC-Direct, a stem cell-based therapy to treat high-risk type 1 diabetes. It is deemed to function as a replacement pancreas.

Browse the full “Endocrine Peptide Test Market By Test Type (Dehydroepiandrosterone Sulfate, Progesterone, Luteinizing Hormone, Thyroid Prolactin, Estradiol, Gonadotropin, Thyroid-stimulating Hormone, and Others), By End-User (Clinics, Healthcare Centers, Hospitals, and Commercial Laboratories), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028.” Report at https://www.zionmarketresearch.com/report/endocrine-peptide-test-market

Global Endocrine Peptide Test Market is segmented as below:

By Test-Type

• Dehydroepiandrosterone Sulphate
• Progesterone
• Luteinizing hormone
• Thyroid Prolactin
• Oestradiol
• Human Chorionic Gonadotropin
• Thyroid-stimulating Hormone
• Others

By End-Users

• Clinics
• Healthcare Centers
• Hospitals
• Commercial Laboratories

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com